American Society of Hematology

SHERPA: Blue

People

  1. Sadelain
    Sadelain
  2. Park
    Park
  3. Wang
    Wang
  4. O'Reilly
    O'Reilly
  5. Curran
    Curran
  6. Bernal
    Bernal
  7. Palomba
    Palomba
  8. Giralt
    Giralt
  9. Kernan
    Kernan
  10. Stefanski
    Stefanski

Groups

  1. Center for Hematologic Malignancies (132)
  2. Department of Medicine (132)
  3. GSK Faculty (132)
  4. Hematologic Malignancies Research (132)
  5. Hematologic Malignancies, Division of (132)
  6. Molecular Pharmacology and Chemistry Program Faculty (132)
  7. Sloan Kettering Institute Faculty (132)
  8. Adult Leukemia (42)
  9. Pediatrics, Department of (33)
  10. Stem Cell Transplantation and Cellular Therapy Service (32)
Search Within
  1. "Michel Sadelain"
Formats
  1. Meeting Abstract (108)
  2. Journal Article (24)
Groups
  1. Center for Hematologic Malignancies (132)
  2. Department of Medicine (132)
  3. GSK Faculty (132)
  4. Hematologic Malignancies Research (132)
  5. Hematologic Malignancies, Division of (132)
  6. Molecular Pharmacology and Chemistry Program Faculty (132)

More Groups

People
  1. Michel Sadelain (132)
  2. Isabelle Riviere (49)
  3. Renier Brentjens (35)
  4. Jae Park (29)
  5. Xiuyan Wang (26)
  6. Richard O'Reilly (22)

More People

Years
  1. 2023 (7)
  2. 2022 (5)
  3. 2021 (3)
  4. 2020 (5)
  5. 2019 (7)
  6. 2018 (4)

More Years

Publications
  1. Blood (132)

Results (132)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GLUT1 overexpression enhances 19-28z CAR-T cell expansion and metabolic fitness
    Meeting Abstract

    Shi, Y.; Kotchetkov, I. S.; Hanina, S. A.; Sadelain, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Role of cell therapy product characteristics in patient response to TAK-940 (CD19(T2)28z1xx chimeric antigen receptor (CAR) T): Biomarker analyses from a phase i study in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Sundaresan, V.; Senechal, B.; Wang, X.; Kashyap, S.; Tong, E.; Joshi, A.; Dash, A.; Sellner, L.; Chen, S.; McAvoy, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Low target antigen expression mediates resistance to BCMA CAR T cell therapy
    Meeting Abstract

    Perica, K.; Nataraj, S.; Sjojstrand, M. L.; Nagel, K.; Pavkovic, E.; Payson, E.; Cuenca, A.; Patel, A.; Chung, D.; Mailankody, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering
    Journal Article

    Odak, A.; Yuan, H.; Feucht, J.; Cantu, V. A.; Mansilla-Soto, J.; Kogel, F.; Eyquem, J.; Everett, J.; Bushman, F. D.; Leslie, C. S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The development of allogeneic tips-derived TCR(-)CAR(+) CD8αβ T cells
    Meeting Abstract

    van der Stegen, S. J. C.; Petrovic, R. M.; Lindenbergh, P. L.; Diop, M. P.; Alexeeva, V.; Xie, H.; Clarke, R.; Valamehr, B.; Rivière, I.; Sadelain, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Combined genetic ablation of CD54 and CD58 in car engineered cytotoxic lymphocytes effectively averts allogeneic immune cell rejection
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; van Ooijen, H.; Varady, E.; Jelcic, M.; Pan, Y.; Momayyezi, P.; Groff, B.; Abujarour, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Overcoming heterogeneity in AML with a novel or-gated HITCAR-1XX platform
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Garcia Angus, A.; Chang, Q.; De Stanchina, E.; Sadelain, M.
    Blood (2022)

    Fulltext@MSK | Save